{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:46:43Z","timestamp":1792057603653,"version":"4.4.0"},"reference-count":31,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Gilead Science Inc.","award":["10323"],"award-info":[{"award-number":["10323"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Background: Bictegravir\/emtricitabine\/tenofovir alafenamide fumarate (BIC\/FTC\/TAF) is a recommended once-daily single-tablet regimen for the treatment of people living with HIV (PLWH). We aimed to assess efficacy, safety, and tolerability of BIC\/FTC\/TAF among PLWH, with a specific focus on people older than 55 years. Methods: We recruited an observational retrospective real-life cohort, including all PLWH who underwent a therapeutic switch to BIC\/FTC\/TAF, independently from the previous treatment regimen (the BICTEL cohort). Longitudinal nonparametric analyses and linear models were built. Results: After 96 weeks of follow-up, 164 PLWH were included, with 106 older than 55. Both the intention-to-treat and the per-protocol analysis showed low rates of virologic failure, independent of the pre-switch anchor drug. At week 96, a significant increase in CD4+ T cell count and in CD4+\/CD8+ ratio was observed, inversely correlated with baseline immune status. Fasting serum lipid profile, total body weight, BMI, and hepatic function were not affected by the switch, without new onset of metabolic syndrome or weight gain. Compared to baseline, we observed a renal function worsening which is worthy of further follow-up. Conclusion: BIC\/FTC\/TAF is an effective, safe, and well-tolerated switching strategy for PLWH, especially among those older than 55.<\/jats:p>","DOI":"10.3390\/v15061222","type":"journal-article","created":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T07:00:02Z","timestamp":1684825202000},"page":"1222","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Immune Reconstitution and Safe Metabolic Profile after the Switch to Bictegravir\/Emtricitabine\/Tenofovir Alafenamide Fumarate among Virologically Controlled PLWH: A 96 Week Update from the BICTEL Cohort"],"prefix":"10.3390","volume":"15","author":[{"given":"Alessandro","family":"Lazzaro","sequence":"first","affiliation":[{"name":"Department of Public Health and Infectious Diseases, Sapienza University of Rome, Policlinico Umberto I of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Bianchini","sequence":"additional","affiliation":[{"name":"Department of Public Health and Infectious Diseases, Sapienza University of Rome, Policlinico Umberto I of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elio","family":"Gentilini Cacciola","sequence":"additional","affiliation":[{"name":"Department of Public Health and Infectious Diseases, Sapienza University of Rome, Policlinico Umberto I of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2855-6425","authenticated-orcid":false,"given":"Ivano","family":"Mezzaroma","sequence":"additional","affiliation":[{"name":"Department of Translational and Precision Medicine, Sapienza University of Rome, AOU Policlinico Umberto I of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Falciano","sequence":"additional","affiliation":[{"name":"Department of Public Health and Infectious Diseases, Sapienza University of Rome, Policlinico Umberto I of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Andreoni","sequence":"additional","affiliation":[{"name":"Department of Public Health and Infectious Diseases, Sapienza University of Rome, Policlinico Umberto I of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Fimiani","sequence":"additional","affiliation":[{"name":"Department of Public Health and Infectious Diseases, Sapienza University of Rome, Policlinico Umberto I of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5621-058X","authenticated-orcid":false,"given":"Letizia","family":"Santinelli","sequence":"additional","affiliation":[{"name":"Department of Public Health and Infectious Diseases, Sapienza University of Rome, Policlinico Umberto I of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Maddaloni","sequence":"additional","affiliation":[{"name":"Department of Public Health and Infectious Diseases, Sapienza University of Rome, Policlinico Umberto I of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2970-7352","authenticated-orcid":false,"given":"Ginevra","family":"Bugani","sequence":"additional","affiliation":[{"name":"Department of Public Health and Infectious Diseases, Sapienza University of Rome, Policlinico Umberto I of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5921-3180","authenticated-orcid":false,"given":"Giancarlo","family":"Ceccarelli","sequence":"additional","affiliation":[{"name":"Department of Public Health and Infectious Diseases, Sapienza University of Rome, Policlinico Umberto I of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1286-467X","authenticated-orcid":false,"given":"Claudio Maria","family":"Mastroianni","sequence":"additional","affiliation":[{"name":"Department of Public Health and Infectious Diseases, Sapienza University of Rome, Policlinico Umberto I of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3571-5677","authenticated-orcid":false,"given":"Gabriella","family":"d\u2019Ettorre","sequence":"additional","affiliation":[{"name":"Department of Public Health and Infectious Diseases, Sapienza University of Rome, Policlinico Umberto I of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,23]]},"reference":[{"key":"ref_1","unstructured":"Gilead Sciences (2023, January 01). Biktarvy\u00ae (Bictegravir, Emtricitabine, and Tenofovir Alafenamide): US Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/."},{"key":"ref_2","unstructured":"Gilead Sciences (2023, January 01). Biktarvy 50 mg\/200 mg\/25 mg Film-Coated Tab-Lets: EU Summary of Product Characteristics. Available online: http:\/\/www.371ema.europa.eu\/."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s40265-018-0896-4","article-title":"Bictegravir: First Global Approval","volume":"78","author":"Markham","year":"2018","journal-title":"Drugs"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"7086","DOI":"10.1128\/AAC.01474-16","article-title":"Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile","volume":"60","author":"Tsiang","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_5","first-page":"526","article-title":"Tenofovir alafenamide (TAF) clinical pharmacology","volume":"29","year":"2021","journal-title":"Le Infez. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e347","DOI":"10.1016\/S2352-3018(18)30091-2","article-title":"Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial","volume":"5","author":"Daar","year":"2018","journal-title":"Lancet HIV"},{"key":"ref_7","unstructured":"Kityo, C., Hagins, D., Koenig, E., Avihingsanon, A., Chetchotisakd, P., Supparatpinyo, K., Gankina, N., Pokrovsky, V., Vo-ronin, E., and Stephens, J.L. (2018, January 4\u20137). Switching to bictegravir\/emtricitabine\/tenofovir alafenamide in women [poster no. 500]. Proceedings of the Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e357","DOI":"10.1016\/S2352-3018(18)30092-4","article-title":"Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-380 blind, multicentre, active-controlled, phase 3, non-inferiority trial","volume":"5","author":"Molina","year":"2018","journal-title":"Lancet HIV"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/S2055-6640(20)30019-4","article-title":"Phase 3 trials of new antiretrovirals are not representative of the global HIV epidemic","volume":"30","author":"Pepperrell","year":"2020","journal-title":"J. Virus Erad."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e207954","DOI":"10.1001\/jamanetworkopen.2020.7954","article-title":"Comparison of Overall and Comorbidity-Free Life Expectancy Between Insured Adults With and Without HIV Infection, 2000\u20132016","volume":"3","author":"Marcus","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S1473-3099(15)00056-0","article-title":"Future challenges for clinical care of an ageing population infected with HIV: A modelling study","volume":"15","author":"Smit","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1089\/apc.2015.0139","article-title":"The HIV care cascade measured over time and by age, sex, and race in a large national integrated care system","volume":"29","author":"Horberg","year":"2015","journal-title":"AIDS Patient Care STDS"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Lazzaro, A., Cacciola, E.G., Borrazzo, C., Innocenti, G.P., Cavallari, E.N., Mezzaroma, I., Falciano, M., Fimiani, C., Mastroianni, C.M., and Ceccarelli, G. (2021). Switching to a Bictegravir Single Tablet Regimen in Elderly People Living with HIV-1: Data Analysis from the BICTEL Cohort. Diagnostics, 12.","DOI":"10.3390\/diagnostics12010076"},{"key":"ref_14","unstructured":"US Food and Drug Administration (2023, January 01). Human Immunodeficiencyvirus-1 Infection: Developing Antiretroviral Drugs for Treatment, Available online: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/human-immunodeficiency-virus-1-infection-developing-antiretroviral-drugs-treatment."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"ref_16","unstructured":"(2023, March 31). Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Available online: https:\/\/rsc.niaid.nih.gov\/sites\/default\/files\/daidsgradingcorrectedv21.pdf."},{"key":"ref_17","unstructured":"European AIDS Clinical Society (2023, January 01). Guidelines Version 11.1. Available online: http:\/\/eacsociety.org."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/hiv.13319","article-title":"Bictegravir\/emtricitabine\/tenofovir alafenamide in older individuals with HIV: Results of a 96-week, phase 3b, open-label, switch trial in virologically suppressed people \u226565\u2009years of age","volume":"24","author":"Maggiolo","year":"2023","journal-title":"HIV Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1093\/jac\/dkz347","article-title":"Switching to bictegravir\/emtricitabine\/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V\/I","volume":"74","author":"Andreatta","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1097\/QAD.0000000000003244","article-title":"High efficacy of switching to bictegravir\/emtricitabine\/tenofovir alafenamide in people with suppressed HIV and preexisting M184V\/I","volume":"36","author":"Sax","year":"2022","journal-title":"AIDS"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.2165\/11633630-000000000-00000","article-title":"HIV-1 antiretroviral resistance: Scientific principles and clinical applications","volume":"72","author":"Tang","year":"2012","journal-title":"Drugs"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1365-2885.2004.00600.x","article-title":"Plasma terminal half-life","volume":"27","author":"Toutain","year":"2004","journal-title":"J. Vet. Pharmacol. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"ofab316","DOI":"10.1093\/ofid\/ofab316","article-title":"Forgiveness of Dolutegravir-Based Triple Therapy Compared With Older Antiretroviral Regimens: A Prospective Multicenter Cohort of Adherence Patterns and HIV-RNA Replication","volume":"8","author":"Parienti","year":"2021","journal-title":"Open Forum Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1093\/jac\/dkv425","article-title":"Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake","volume":"71","author":"Elliot","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_25","first-page":"e26009","article-title":"Real-life monocentric Biktarvy cohort from Perugia. HIV Glasgow 2022, Poster P129","volume":"25","author":"Benedetti","year":"2022","journal-title":"J. Int. AIDS Soc."},{"key":"ref_26","unstructured":"d\u2019Arminio Monforte, A., Tavelli, A., Cingolani, A., Taramasso, L., Mussini, C., Piconi, S., Calcagno, A., Orofino, G., Cicalini, S., and Castagna, A. (2023, January 01). Effectiveness of Bictegravir\/Emtricitabine\/Tenofovir Alafenamide (BIC\/FTC\/TAF) as Switch Strategy in Virologically Suppressed: Real-World Data from the ICONA Cohort. HIV Glasgow 2022, Poster P098. Available online: https:\/\/hivglasgow.org\/wp-content\/uploads\/2023\/01\/P098_dArminio_Monforte.pdf."},{"key":"ref_27","unstructured":"Trottier, B., Antinori, A., De Wet, J., Duvivier, C., Elinav, H., Esser, S., Ghosn, J., den Hollander, J., Lamber, J., and Milinkovic, A. (2023, January 01). Bictegravir\/emtricitabine\/tenofovir alafenamide (B\/F\/TAF) for the treatment of people living with HIV: 24-month (24M) analyses by age, race, sex, adherence and late presentation in a multi-country cohort study. HIV Glasgow 2022, Poster P067. Available online: https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jia2.26009."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Kehler, D.S., Milic, J., Guaraldi, G., Fulop, T., and Falutz, J. (2022). Frailty in older people living with HIV: Current status and clinical management. BMC Geriatr., 22.","DOI":"10.1186\/s12877-022-03477-7"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"101412","DOI":"10.1016\/j.eclinm.2022.101412","article-title":"Evidence synthesis evaluating body weight gain among people treating HIV with antiretroviral therapy-a systematic literature review and network meta-analysis","volume":"48","author":"Kanters","year":"2022","journal-title":"EClinicalMedicine"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Saumoy, M., Sanchez-Quesada, J.L., Ordo\u00f1ez-Llanos, J., and Podzamczer, D. (2021). Do All Integrase Strand Transfer Inhibitors Have the Same Lipid Profile? Review of Randomised Controlled Trials in Na\u00efve and Switch Scenarios in HIV-Infected Patients. J. Clin. Med., 10.","DOI":"10.3390\/jcm10163456"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1097\/QAD.0000000000002853","article-title":"Dolutegravir is not associated with weight gain in antiretroviral therapy experienced geriatric patients living with HIV","volume":"35","author":"Guaraldi","year":"2021","journal-title":"AIDS"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/6\/1222\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:40:05Z","timestamp":1760125205000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/6\/1222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,23]]},"references-count":31,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["v15061222"],"URL":"https:\/\/doi.org\/10.3390\/v15061222","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,23]]}}}